Xeris Pharmaceuticals (XERS) spiked 12% in Friday’s after-hours trading after a filing disclosed that Soros Fund Management, LLC holds a 5.3% stake in the company with ~2.5M common shares.Soros Fund Management was founded in 1969 by 89-year old hedge fund tycoon and billionaire George Soros.Xeris’s lead product, Gvoke, is a ready-to-use glucagon product for diabetic patients experiencing severe hypoglycemia, which has been approved as a prefilled syringe (PFS) and autoinjector (HypoPen).The HypoPen was launched on July 1, making it the first ready-to-use glucagon in a premixed autoinjector, with no visible needle.“We are excited to announce that Gvoke HypoPen is now …read more
Source:: Yahoo Finance
